Vaxcyte (PCVX) Cash from Financing Activities (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Cash from Financing Activities of $601.6 million for Q1 2026, up 79159.95% year-over-year from N/an in Q1 2025, and up 24882.68% quarter-over-quarter from $2.4 million in Q4 2025.
Vaxcyte (PCVX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Cash from Financing Activities for 8 consecutive years, with $601.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 79159.95% year-over-year to $601.6 million; the TTM figure through Mar 2026 stood at $602.8 million (down 63.04% YoY), while the FY2025 annual figure was $2.0 million, down 99.92% from the prior year.
- Cash from Financing Activities improved to $601.6 million in Q1 2026 per PCVX's latest filing, from $2.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $1.5 billion in Q3 2024 and bottomed at -$3.7 million in Q3 2025.
- Historically, Cash from Financing Activities has averaged $267.9 million across 5 years, with a median of $48.6 million in 2023.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities slumped 100.24% — and 2026, when it soared 79159.95%.
- Vaxcyte's Cash from Financing Activities stood at $656.6 million in 2022, then slumped by 99.58% to $2.7 million in 2023, then jumped by 79.41% to $4.9 million in 2024, then sank by 50.93% to $2.4 million in 2025, then jumped by 24882.68% to $601.6 million in 2026.
- Business Quant data shows PCVX's Cash from Financing Activities at $601.6 million in Q1 2026, $2.4 million in Q4 2025, and -$3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 5.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.70 Mn |
| Jun 30, 2026 | 5.70 Mn |
| Mar 31, 2026 | 601.58 Mn |
| Mar 31, 2026 | 601.58 Mn |
| Dec 31, 2025 | 2.41 Mn |
| Dec 31, 2025 | 2.41 Mn |
| Sep 30, 2025 | -3.67 Mn |
| Sep 30, 2025 | -3.67 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Mar 31, 2025 | 759,000.00 |
| Mar 31, 2025 | 759,000.00 |
| Dec 31, 2024 | 4.91 Mn |
| Dec 31, 2024 | 4.91 Mn |
| Sep 30, 2024 | 1.52 Bn |
| Sep 30, 2024 | 1.52 Bn |
| Jun 30, 2024 | 110.37 Mn |
| Jun 30, 2024 | 110.37 Mn |
| Mar 31, 2024 | 818.20 Mn |
| Mar 31, 2024 | 818.20 Mn |